Used in the treatment of hypercholesterolemia and other lipid disorders by targeting and inhibiting PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein (LDL) cholesterol from the bloodstream. By blocking PCSK9, this antibody increases the number of LDL receptors on liver cells, significantly lowering circulating LDL cholesterol levels. It is particularly beneficial for patients with familial hypercholesterolemia or those at high risk of cardiovascular events who do not achieve sufficient control with statins alone. Administered via subcutaneous injection, it offers a long-acting option for chronic management of high cholesterol, contributing to reduced incidence of heart attacks and strokes.